HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Traditional Chinese Medicine

645.297

-32.045-4.73%

Number of Gainers:1

Number of Losers:9

Number of Flat:1

PE:- -

High:677.461

Open:677.461

Low:640.165

Close:677.343

Volume:146.86M

Turnover:387.06M

Market Cap:67.18B

Float Cap:45.62B

Loading ...

Tong Ren Tang Technologies - Board Does not Declare the Distribution of an Interim Dividend

THOMSON REUTERS

Tong Ren Tang Tech FY26 H1 Profit Attributable to Owners Drops 26.43% to RMB 249.14 Million; Revenue Falls 19.1% to RMB 3.02 Billion

China's Dawnrays Pharmaceutical H1 Revenue Falls on Lower Procurement Prices

Guangzhou Baiyunshan Pharmaceutical - Disposal of First New Underlying Assets of Gp Corp. to Industrial Securities Asset Management for Rmb146.3 Mln

THOMSON REUTERS

Baiyunshan's First-Half Profit Plunges 16.7%: Herbal Tea Business Under Pressure, Lingering Legal Battle Over Jinge Resurfaces

China's Gushengtang Holdings HY Revenue Rises on Offline Medical Institution Expansion

Shandong Boan Biotech Enters RMB 75 Million Sale-and-Leaseback Deal with Industrial Bank Financial Leasing

Huawei Plans for More AI Pharma Tie-Ups, Says Healthcare President

Shineway Pharma Surges Over 5% in Afternoon Trade as H1 Revenue Drops 28.5% to RMB 1.181 Billion

Shineway Pharma Posts 23.7% Profit Decline in Interim Results

China Shineway Pharmaceutical - Profit for H1 Rmb469.2 Mln

THOMSON REUTERS

China Shineway Pharmaceutical - Declared 2026 Second Interim Dividend of RMB80 Cents Per Share

THOMSON REUTERS

China Shineway FY26 H1 Profit Drops 23.7% to RMB 469.16 Million; Revenue Falls 28.5% to RMB 1.18 Billion

China Shineway Pharma Declares RMB 0.8 Fy2026 Second Interim Dividend

HK Stock Market Highlights: Butong Group's Interim Profit Soars 98.28%, Plans AI Enhancements for Core Products

China's Kindstar Globalgene H1 Loss Narrows After Oncology Testing Expansion

China's Zhongzhi Pharmaceutical H1 Revenue Falls 10%

PuraPharm FY26 H1 Net Loss Narrows 34.7% to Hk$14.24 Million; Revenue Falls 7.3% to Hk$159.67 Million

Zhongzhi Pharm Posts Interim Results with 3.79% Rise in Net Profit Attributable to Shareholders

Zhongzhi Pharma FY26 H1 Profit Attributable to Owners Rises 3.8% to RMB 9.1 Million; Revenue Falls 10.3% to RMB 790 Million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/BK1606/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1606","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1606\",,,,,undefined,":{"symbol":"BK1606","market":"HK","secType":"PLATE","nameCN":"Traditional Chinese Medicine","latestPrice":645.29736,"timestamp":1788163726135,"preClose":677.3426,"halted":0,"volume":146858435,"delay":0,"changeRate":-0.04731,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-32.045227,"latestTime":"08-31 16:00:00","open":677.46094,"high":677.46094,"low":640.165,"amount":387064647,"amplitude":0.055062,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788226200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"pbRate":0.695189,"peRate":12.446339,"turnoverRate":0.008344,"increases":1,"decrements":9,"flats":1,"marketCap":67179754048,"floatMarketCap":45620053632},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1606\",,,,,undefined,":{"symbol":"BK1606","high":677.46094,"amplitude":0.055062,"preClose":677.3426,"low":640.165,"pbRate":"0.695189","latestPrice":645.29736,"volume":146858435,"delay":0,"open":677.46094,"prevYearClose":830.6915,"prevWeekClose":677.343,"prevMonthClose":681.608,"prevQuarterClose":629.733,"fiveDayClose":659.047,"twentyDayClose":683.014,"sixtyDayClose":704.754,"secType":"PLATE","market":"HK","turnoverRate":0.008344,"peRate":12.446339,"marketCap":67179754048,"floatMarketCap":45620053632,"timestamp":1788163726135,"nameCN":"Traditional Chinese Medicine"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1606\",,,,undefined,":{"bkCode":"BK1606","up":1,"down":9,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1606\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662062493","title":"Tong Ren Tang Technologies - Board Does not Declare the Distribution of an Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2662062493","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662062493?lang=en_us&edition=fundamental","pubTime":"2026-08-28 19:13","pubTimestamp":1787915588,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44P0YW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","01666","BK1606","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662706241","title":"Tong Ren Tang Tech FY26 H1 Profit Attributable to Owners Drops 26.43% to RMB 249.14 Million; Revenue Falls 19.1% to RMB 3.02 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2662706241","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662706241?lang=en_us&edition=fundamental","pubTime":"2026-08-28 19:13","pubTimestamp":1787915584,"startTime":"0","endTime":"0","summary":"Tong Ren Tang Tech FY26 H1 profit attributable to owners drops 26.43% to RMB 249.14 million; revenue falls 19.1% to RMB 3.02 billionTong Ren Tang Technologies posted a 26.43% drop in profit attributab","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL3f6wD5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK0086","BK0196","BK0097","LU1688375341.USD","BK1583","BK0239","01666","BK1606","BK0012","BK1515","BK0028","600085","BK0188","BK1191","BK0113"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662172061","title":"China's Dawnrays Pharmaceutical H1 Revenue Falls on Lower Procurement Prices","url":"https://stock-news.laohu8.com/highlight/detail?id=2662172061","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662172061?lang=en_us&edition=fundamental","pubTime":"2026-08-28 18:28","pubTimestamp":1787912881,"startTime":"0","endTime":"0","summary":"China's Dawnrays Pharmaceutical H1 revenue falls on lower procurement pricesOverviewChina pharmaceutical maker's interim revenue fell 13.4% yr/yr on lower sales of key productsProfit attributable to o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nL1N44P0BX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0326950275.SGD","LU2242644610.SGD","LU2097828474.EUR","LU2328871848.SGD","LU2097828714.EUR","LU0455707207.USD","LU0463099449.HKD","BK1606","LU0244354667.USD","BK1583","BK1589","LU2097828631.EUR","LU2488822045.USD","BK1191","LU2097828557.USD","LU1188198961.HKD","KURE","02348","LU0502904849.HKD","03737","LU2097828805.USD","01801","BK1161","LU1969619763.USD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662406854","title":"Guangzhou Baiyunshan Pharmaceutical - Disposal of First New Underlying Assets of Gp Corp. to Industrial Securities Asset Management for Rmb146.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662406854","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662406854?lang=en_us&edition=fundamental","pubTime":"2026-08-28 16:48","pubTimestamp":1787906907,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44O1M2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK1197","BK0175","00874","BK0188","BK1521","BK0070","BK0012","BK0096","600332","BK0196","BK0239","BK0183","BK0028","BK1515","BK1606","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139991411","title":"Baiyunshan's First-Half Profit Plunges 16.7%: Herbal Tea Business Under Pressure, Lingering Legal Battle Over Jinge Resurfaces","url":"https://stock-news.laohu8.com/highlight/detail?id=1139991411","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139991411?lang=en_us&edition=fundamental","pubTime":"2026-08-28 14:31","pubTimestamp":1787898681,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (SHA: 600332) has released its interim report for the first half of 2026, revealing a complex financial picture. The company recorded...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00874","BK1606","BK0012","600332","BK0239","BK1521","BK0028","BK0070","BK0097","BK0183","BK0196","BK1191","BK1515","BK1197","BK0188","BK0175","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662055140","title":"China's Gushengtang Holdings HY Revenue Rises on Offline Medical Institution Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2662055140","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662055140?lang=en_us&edition=fundamental","pubTime":"2026-08-28 12:25","pubTimestamp":1787891112,"startTime":"0","endTime":"0","summary":"China's Gushengtang Holdings HY revenue rises on offline medical institution expansionOverviewChina traditional medicine provider's half-year revenue rose 10.6% yr/yr to RMB1.65 blnNet profit attribut","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nL1N44P04A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01681","BK1191","02273","BK1606","BK1219"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662086347","title":"Shandong Boan Biotech Enters RMB 75 Million Sale-and-Leaseback Deal with Industrial Bank Financial Leasing","url":"https://stock-news.laohu8.com/highlight/detail?id=2662086347","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662086347?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:34","pubTimestamp":1787841244,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotech enters RMB 75 million sale-and-leaseback deal with Industrial Bank Financial LeasingShandong Boan Biotechnology entered a sale-and-leaseback with Industrial Bank Financial Leasin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL1FHKB4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0012","02186","LU0572940350.SGD","LU0572939691.SGD","BK1606","BK0183","06955","BK0015","BK0028","HK0000181112.HKD","LU0821914370.USD","HK0000181138.USD","BK0187","LU1580142542.USD","BK1191","LU1781817850.SGD","601166","BK1583","BK0278","LU0264606111.USD","BK1161","LU1048596156.SGD","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662771484","title":"Huawei Plans for More AI Pharma Tie-Ups, Says Healthcare President","url":"https://stock-news.laohu8.com/highlight/detail?id=2662771484","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662771484?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:25","pubTimestamp":1787819119,"startTime":"0","endTime":"0","summary":"Huawei plans for more AI pharma tie-ups, says healthcare presidentSHANGHAI, Aug 27 (Reuters)-Chinese technology conglomerate Huawei plans to expand its AI cooperation with local pharmaceuticalfirmsint","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL6N44O077:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1197","BK1521","00874","BK1606","600332","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136394948","title":"Shineway Pharma Surges Over 5% in Afternoon Trade as H1 Revenue Drops 28.5% to RMB 1.181 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1136394948","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136394948?lang=en_us&edition=fundamental","pubTime":"2026-08-27 15:00","pubTimestamp":1787814026,"startTime":"0","endTime":"0","summary":"Shineway Pharma (02877) saw its share price spike as much as 12% in the afternoon session before settling at a 4.92% gain, trading at HKD 8.33 with turnover reaching HKD 54.234 million.The company...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","02877","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119807517","title":"Shineway Pharma Posts 23.7% Profit Decline in Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1119807517","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119807517?lang=en_us&edition=fundamental","pubTime":"2026-08-27 12:18","pubTimestamp":1787804298,"startTime":"0","endTime":"0","summary":"Shineway Pharma (02877) has released its interim results for the 2026 fiscal year, reporting a turnover of RMB 1.181 billion for the period, a year-on-year decrease of 28.5%. Net profit for the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02877","BK1606","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662727326","title":"China Shineway Pharmaceutical - Profit for H1 Rmb469.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662727326","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662727326?lang=en_us&edition=fundamental","pubTime":"2026-08-27 12:02","pubTimestamp":1787803367,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nPLX9D6QT8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","02877","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662472737","title":"China Shineway Pharmaceutical - Declared 2026 Second Interim Dividend of RMB80 Cents Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2662472737","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662472737?lang=en_us&edition=fundamental","pubTime":"2026-08-27 12:02","pubTimestamp":1787803367,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nPLX9D6QT8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02877","BK1606","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662324727","title":"China Shineway FY26 H1 Profit Drops 23.7% to RMB 469.16 Million; Revenue Falls 28.5% to RMB 1.18 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2662324727","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662324727?lang=en_us&edition=fundamental","pubTime":"2026-08-27 12:02","pubTimestamp":1787803328,"startTime":"0","endTime":"0","summary":"China Shineway FY26 H1 profit drops 23.7% to RMB 469.16 million; revenue falls 28.5% to RMB 1.18 billionChina Shineway Pharmaceutical posted profit of RMB 469.16 million, down 23.7%, as earnings per s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDLbJmW6g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","BK1191","02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662273297","title":"China Shineway Pharma Declares RMB 0.8 Fy2026 Second Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2662273297","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662273297?lang=en_us&edition=fundamental","pubTime":"2026-08-27 12:02","pubTimestamp":1787803327,"startTime":"0","endTime":"0","summary":"China Shineway Pharma declares RMB 0.8 FY2026 second interim dividendChina Shineway Pharmaceutical Group declared a second interim dividend for fiscal 2026 of RMB 0.8 per share.Dividend will be paid in HKD at HKD 0.93 per share, based on an exchange rate of RMB 1 to HKD 1.17.Shares trade ex-dividend on Sept. 9; record date is Sept. 14; payment date is Sept. 25.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Shineway Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on August 27, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL1cvT0X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02877","BK1191","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135532057","title":"HK Stock Market Highlights: Butong Group's Interim Profit Soars 98.28%, Plans AI Enhancements for Core Products","url":"https://stock-news.laohu8.com/highlight/detail?id=1135532057","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135532057?lang=en_us&edition=fundamental","pubTime":"2026-08-27 09:17","pubTimestamp":1787793443,"startTime":"0","endTime":"0","summary":"Major announcements in focus:BIDU-SW (09888) has voluntarily converted to dual-primary listing on the Hong Kong Stock Exchange. CHINA BAOLI TEC (00164) has made significant progress deploying its dry...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456827905.SGD","BK1575","LU1481107354.HKD","BK1615","LU0417516902.SGD","TCHI","LU0588546209.SGD","LU0417516738.SGD","LU0823426308.USD","LU0708995583.HKD","LU0043850808.USD","CHAT","LU1048588211.SGD","LU0871576103.HKD","LU0320764599.SGD","LU0762542818.HKD","BK1606","AGIX","VTHR","LU2778985437.USD","AIPO","LU0287142896.SGD","HK0000306701.USD","HK0000320264.USD","LU0326950275.SGD","LU0831093199.SGD","LU0229945570.USD","LU0164865239.USD","LU1831875114.USD","LU0315179316.USD","KCAI","LU0173614495.USD","BK1193","01681","LU0348825331.USD","LU0630378429.USD","BK4585","LU0197773160.USD","LU0359201612.USD","LU0052750758.USD","LU0163747925.USD","LU0244354667.USD","BK1229","LU0819121731.USD","LU2039709279.SGD","BIDU","LU1115378108.SGD","LU1188198961.HKD","BK1570","LU1328615791.USD","BK1594","LU0228367735.SGD","BK1095","LU0821914370.USD","LU0640798160.USD","09888","BK1191","06090","BK1609","LU0762540952.USD","LU0463099449.HKD","LU0348735423.USD","BK1530","LU0630378692.HKD","BK1258","BK1125","BK4588","LU0823426480.USD","LU0762541174.USD","LU0039217434.USD","SG9999014674.SGD","LU2476274308.USD","QTOC","VXUS","LU0359201885.HKD","BK1588","SG9999002828.SGD","LU0197773673.USD","LU0856984785.SGD","IE0034224299.USD","89888","HK0000306685.HKD","LU1023057109.AUD","IE00B3M56506.USD","SG9999002463.SGD","LU0359202008.SGD","LU0531971595.HKD","00836","BK1207","LU0149721374.USD","LU1048596156.SGD","ARTY","LU0051755006.USD","00164","BK1587","LU0072462343.USD","LU0307460666.USD","HK0000320223.HKD","LU0164880469.USD","LU0543330566.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662283697","title":"China's Kindstar Globalgene H1 Loss Narrows After Oncology Testing Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2662283697","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662283697?lang=en_us&edition=fundamental","pubTime":"2026-08-27 06:35","pubTimestamp":1787783742,"startTime":"0","endTime":"0","summary":"China's Kindstar Globalgene H1 loss narrows after oncology testing expansionOverviewChina diagnostics testing firm's H1 revenue rose 3.7% yr/yrNet loss for H1 narrowed 44.7% yr/yr as gross profit marg","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL1N44N17B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1219","09960","BK1606","BK1587","BK1191","03737"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662715194","title":"China's Zhongzhi Pharmaceutical H1 Revenue Falls 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662715194","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662715194?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:36","pubTimestamp":1787744170,"startTime":"0","endTime":"0","summary":"China's Zhongzhi Pharmaceutical H1 revenue falls 10%OverviewChina pharmaceutical maker's half-year revenue fell 10.3% yr/yrProfit attributable to owners rose 3.8% yr/yrGross profit and margin declined","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL1N44N0G0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1593","BK1606","00460","01681","03692","BK1191","BK1589","BK1583","03737","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662715196","title":"PuraPharm FY26 H1 Net Loss Narrows 34.7% to Hk$14.24 Million; Revenue Falls 7.3% to Hk$159.67 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662715196","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662715196?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:35","pubTimestamp":1787744109,"startTime":"0","endTime":"0","summary":"PuraPharm FY26 H1 net loss narrows 34.7% to HK$14.24 million; revenue falls 7.3% to HK$159.67 millionPuraPharm posted revenue of HK$159.67 million, down 7.3% year over year, for the six months ended J","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL5fjnwB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","BK1191","01498"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132103208","title":"Zhongzhi Pharm Posts Interim Results with 3.79% Rise in Net Profit Attributable to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=1132103208","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132103208?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:32","pubTimestamp":1787743935,"startTime":"0","endTime":"0","summary":"Zhongzhi Pharm (03737) has announced its interim financial results for the six months ended June 30, 2026, reporting a total revenue of RMB 790 million, a year-on-year decline of 10.28%.During the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03737","BK1191","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662715347","title":"Zhongzhi Pharma FY26 H1 Profit Attributable to Owners Rises 3.8% to RMB 9.1 Million; Revenue Falls 10.3% to RMB 790 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662715347","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662715347?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:25","pubTimestamp":1787743504,"startTime":"0","endTime":"0","summary":"Zhongzhi Pharma FY26 H1 profit attributable to owners rises 3.8% to RMB 9.1 million; revenue falls 10.3% to RMB 790 millionZhongzhi Pharmaceutical posted revenue of RMB 789.96 million, down 10.3% from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL320KVG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","03737","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":64,"code":"91000000","status":"200"}]}}